GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine
about
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressantsNeuroplasticity and the next wave of antidepressant strategiesPotential of Glutamate-Based Drug Discovery for Next Generation AntidepressantsA Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical CorrelatesAntidepressant mechanism of ketamine: perspective from preclinical studiesAntidepressant actions of ketamine: from molecular mechanisms to clinical practiceOptogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions.Glycogen synthase kinase-3β inhibition in the medial prefrontal cortex mediates paradoxical amphetamine action in a mouse model of ADHD.The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stressGlutamate and its receptors in the pathophysiology and treatment of major depressive disorderDIXDC1 contributes to psychiatric susceptibility by regulating dendritic spine and glutamatergic synapse density via GSK3 and Wnt/β-catenin signaling.Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.NMDA Receptors Regulate the Structural Plasticity of Spines and Axonal Boutons in Hippocampal Interneurons.Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeuticsCircadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder.Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections.GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamineAnti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism.Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar DepressionSpine synapse remodeling in the pathophysiology and treatment of depression.Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylationNeuronal correlates of depression.GABAergic control of depression-related brain statesLongitudinal Effects of Ketamine on Dendritic Architecture In Vivo in the Mouse Medial Frontal CortexGroup II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in ratsMolecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and ScopolamineModulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13).Mechanisms underlying the neuroprotective effect of brain reserve against late life depression.Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections.Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish.A Circadian Genomic Signature Common to Ketamine and Sleep Deprivation in the Anterior Cingulate Cortex.New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs.Targeting glutamate signalling in depression: progress and prospects.Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular ActionsPPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.
P2860
Q21129276-DF0F3E0D-896A-4842-A3DE-693A943BC78AQ21129480-50025BBC-B055-4274-AD7F-FD450B9B862AQ26782274-C67E85E8-D612-40A5-AE3D-8ECD395DAAC5Q26786354-218B04F6-BC1E-47F3-8ACC-5C5A39F1B340Q26800231-D94BF315-E98E-409B-90F3-909D4F671C56Q26995879-D2245954-0BF4-4D33-B442-A7CE1A729A94Q27328579-4BD1C021-0FFF-465C-95BC-429ECDA1667EQ30414710-A317F529-4245-47B0-823A-6C9D2A68AD47Q30651146-56C7E735-1489-417E-9667-BAE82EA1DA60Q30711088-A910499B-89C5-4266-B913-C6B6A13FA20FQ33574930-A30E8E4E-F4F9-4B7D-98B0-E2A4D326B1DDQ33604879-BEC4B17C-136F-4ADA-A318-B782C4BBFBDDQ33785739-7E1AAEBD-CB46-4728-9989-5FC144098CE8Q33874459-2B7EB182-1726-494C-85C0-7E83C127AC0EQ34444632-FE377FA0-AB37-4C3C-BDDE-84A637460849Q34445122-AEC88F0B-26EB-4DCD-BE19-BC62B37824B7Q34475595-B6D98AAF-8782-4A61-A8B3-9C815A5CAFC8Q34661281-31B85298-B5F2-4748-89A6-DF6DEDB6E82EQ34729421-2645B4C2-159F-4B7E-B475-22AE486FF16EQ35150163-5BA75384-FA68-4261-A7B3-4252CABB74E3Q35586357-403BCD83-4928-4B1A-8568-4E67FFCB6740Q35763203-7C8F41DF-72E1-49C4-9670-C1891610211DQ35836787-EEBACE16-5ABE-4FEE-9D8E-D57C3CC90CD9Q36363351-F4CEF146-8943-4D7D-B87A-22AF21DC8E5EQ36451816-4C5E6C51-73A1-4371-961E-F73D5706C9C8Q36668325-8CC6D934-9BDA-4A44-B3AE-FEA95321FE7DQ36760919-D76F651F-1872-49FF-BFCE-BC290EA48DFEQ37067121-00BAEE34-5BDB-439E-96DF-B4A7EDB0C279Q37668009-C77A8693-B373-4349-9109-2B879D5F9FC2Q37741989-498A9BB5-BABB-447F-9418-F88D87786583Q38175828-3BABC7B6-0F21-4AF3-B033-740EE08645F5Q38194996-DC286E3F-9631-4FDD-879D-98E874B583D1Q38331726-ECD9AE2E-D1F5-45B2-9A9C-B9C6B02B5294Q38434930-817F0CE5-BA26-4873-A5E9-7EBC37E715BAQ38650284-C4759D00-650F-4E46-92B5-FA8175B9B0BCQ38743867-D6DBE8C8-E89F-4753-BAF0-E2BC9BCEBA96Q38770806-68AEE980-C28A-4072-BD81-A27943FC7AAAQ38776236-E8BAEADA-C3A6-4B11-8876-807C674CCE2DQ38793772-10A9973B-7D8F-4228-86B9-216FD681B089Q38803371-446E1291-509B-416E-8716-D54713EC4A37
P2860
GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
GSK-3 inhibition potentiates t ...... subthreshold doses of ketamine
@en
GSK-3 inhibition potentiates t ...... ubthreshold doses of ketamine.
@nl
type
label
GSK-3 inhibition potentiates t ...... subthreshold doses of ketamine
@en
GSK-3 inhibition potentiates t ...... ubthreshold doses of ketamine.
@nl
prefLabel
GSK-3 inhibition potentiates t ...... subthreshold doses of ketamine
@en
GSK-3 inhibition potentiates t ...... ubthreshold doses of ketamine.
@nl
P2093
P2860
P356
P1476
GSK-3 inhibition potentiates t ...... subthreshold doses of ketamine
@en
P2093
Ashley E Lepack
George K Aghajanian
Jason M Dwyer
Manabu Fuchikami
Ronald S Duman
Rong-Jian Liu
P2860
P2888
P304
P356
10.1038/NPP.2013.128
P407
P577
2013-05-17T00:00:00Z